EDITOR'S DESK

  • The Debate On Standards In Biologics Development Heats Up
    The Debate On Standards In Biologics Development Heats Up

    Though it’s only natural to expect animated scientific discussion between the FDA and USP which have long been partners-in-science, I found myself caught off-guard by just how firmly the FDA has been putting its foot down and making its thoughts known on the role certain standards — in particular, USP monographs — should (or should not play) in biologics development.

FDA’s “Show Me The Data” A Recipe For Tailored Biosimilar Development?

In this first of what will be a two-part article, USP's Fouad Atouf highlights the challenges presented by the FDA’s newest guidance while remaining optimistic that the large amount of data recommended today will open doors to more efficient development in the (hopefully) near future.

Why We Should Celebrate The FDA’s Biosimilar Comparative Analytics Guidance

Despite the importance of the process the FDA is outlining in the guidance, I’ve surprisingly heard little chatter — positive or negative — about what the agency is now outlining and what this may mean for biosimilars and the biosimilar regulatory paradigm moving forward. Here are a couple of the biggest takeaways to note.

3 Countries To Watch In The MENA Region

Though there is a large handful of countries that, to date, don’t have biosimilar pathways established, a few countries have been slowly gearing up to be leaders in paving the way for biologics and biosimilars. In this article, I’ll discuss the potential of these three markets, as well as the business considerations Challand highlighted for companies considering entering the MENA region.

MENA: Biosimilar Market Challenges And Regulatory Considerations

Throughout her presentation, Challand gave us a good look at the current state of the biologics market in MENA and the ongoing educational and collaborative efforts that could help shape the markets in this region. She also shared several important considerations for regulators and biosimilar companies looking to expand their business to MENA.

More From Our Editors

GUEST CONTRIBUTORS

  • 4 (More) Microbiological Root Cause Analyses Lessons From Sherlock Holmes
    4 (More) Microbiological Root Cause Analyses Lessons From Sherlock Holmes

    Bias can take many forms and is often not easily recognized by an investigator. Sherlock Holmes was keenly aware of bias' potential impacts and so did not allow bias generated through speculation, random hypothesis, or previous experience to determine or redirect the course of his investigations. Applying more of Holmes’ famous observations and investigative principles can uncover hidden bias and greatly increase an investigator’s chance of finding that elusive definitive root cause.

  • Applications For Single-Use Systems In Biosimilar Development
    Applications For Single-Use Systems In Biosimilar Development

    Exploring the benefits, challenges, and future of disposable systems in biosimilar manufacturing.

  • Cutting Packaging Costs: What Life Sciences Can Learn From Consumer Packaged Goods
    Cutting Packaging Costs: What Life Sciences Can Learn From Consumer Packaged Goods

    Industries can (and should) learn from one another. As the life sciences market continues to become more competitive and social pressure to reduce healthcare costs increases, consumer packaged goods (CPG) approaches and strategies to cut packaging costs can be applied to life sciences to achieve these objectives. 

  • IPR For Biosimilars: Examining The Benefits And Drawbacks

    Whether Inter Partes Review (IPR) is the right choice for biosimilar developers will depend on the particular circumstances surrounding each drug candidate. But given the benefits of IPR proceedings, they must at least be considered as a potential tool for challenging patents.

  • Equipment Change Control For GMP Production Facilities — Proving It All Works

    The first article in this two-part series outlined the six primary stages of equipment change control and discussed the first two stages: (1) determining the equipment utility/IT requirements and (2) pre-installation assessment, utility evaluation, and remediation. This article describes the final four stages of this process: (3) evaluating the impact of new equipment installation on previously validated utilities, (4) executing validations for new equipment, (5) review of equipment turn-over packages and validation reports, and (6) performing change control effectiveness checks.

More From Guest Contributors

BIOPROCESSING WHITE PAPERS

  • Cell Growth Performance In Single-Use Bags

    Achieving consistent cell growth is critically important to the biotech industry. To optimize the final drug product output the current industry trends are towards higher cell densities and protein titers.

  • Speed Up The Pace Of Chemical Research And Development

    Today’s chemical development labs are busy places that create fascinating new chemicals, new formulations and new products that boost the bottom line. But are these labs as efficient as they could be?

More Bioprocessing White Papers

FREE CLEANING VALIDATION E-BOOK

Learn how to employ science-, risk-, and statistics-based approaches to cleaning and cleaning validation at your facility with this free, 100-page e-book, written by a global team of cleaning validation experts, pharmaceutical toxicologists, statisticians, and Six Sigma professionals.

INDUSTRY INSIGHTS

  • A Framework For Measuring Training ROI Using Quality Metrics
    A Framework For Measuring Training ROI Using Quality Metrics

    This article proposes an approach using data-driven insights from standard quality culture and performance metrics, with CoPQ calculations, to measure training return on investment (ROI). 

  • Best Practices For Compliance With The New Elemental Impurities Requirements
    Best Practices For Compliance With The New Elemental Impurities Requirements

    New requirements for control of elemental impurities went into effect at the beginning of 2018, replacing the longstanding requirements for heavy metals.  Elemental impurities guidances are based on modern safety considerations specific to the elements identified. 

  • Serialization In Practice: How Manufacturers Can Ensure Compliance
    Serialization In Practice: How Manufacturers Can Ensure Compliance

    Pharmaceutical manufacturers cannot limit responsibility for DSCSA compliance to just the engineers and operators involved in processing and packaging.

  • Cryogenic Transport For Gene Therapy Products — The Pros And Cons
    Cryogenic Transport For Gene Therapy Products — The Pros And Cons

    Temperature-controlled packages used for the transport of gene therapy products use a combination of thermal insulators or thermoregulators to decrease the heat transfer rate from outside of the shipper to the inside. In this two-part article, we will explore common methods of temperature-controlled transportation and delve into their pros and cons. In Part 1, we focus on passive cryogenic options.

  • Personalized Medicine – How the Batch Size Will Change Our Lives
    Personalized Medicine – How the Batch Size Will Change Our Lives

    The ability to understand how an individual’s genetic inheritance affects the body’s response to medicine offers tremendous safety and economic advantages. It also impacts the marketing strategy of the biopharmaceutical industry and may drive manufacturers to a wider family of medicines made in smaller batch quantities. This change would cause a shift in manufacturing facility and process design paradigms. Will disposables be the wave of the future or will old paradims prevail?

    By Alfredo Canhoto, Associate Director, Technical Solutions Practice, ProPharma

More Industry Insights

LIFE SCIENCE INDUSTRY EVENTS

Cleanroom Microbiology – A Foundational Introduction July 18 - 18, 2019
1pm-2:30pm EDT, Online Training
FDA's eCTD Ad-Promo Guidance Is Finalized: Are You Ready? August 7 - 7, 2019
1pm-2:30pm EDT, Online Training
Understanding Aseptic Technique and Cleanroom Behavior – Avoiding Human Error August 8 - 8, 2019
1pm-2:30pm EDT, Online Training
More Industry Events

TRAINING COURSES

Cleanroom Microbiology – A Foundational Introduction July 18 - 18, 2019
1pm-2:30pm EDT, Online Training
FDA's eCTD Ad-Promo Guidance Is Finalized: Are You Ready? August 7 - 7, 2019
1pm-2:30pm EDT, Online Training
Understanding Aseptic Technique and Cleanroom Behavior – Avoiding Human Error August 8 - 8, 2019
1pm-2:30pm EDT, Online Training
More Upcoming Courses